Ruling found patent doesn’t claim drug’s key complex, MSN says Move is latest in flurry of district, appeals court filings A Novartis AG patent for Entresto revived this month doesn’t cover the ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...

No­var­tis is the lat­est drug­mak­er to sue the gov­ern­ment for al­leged­ly re­ject­ing its pro­posed mod­el to dis­trib­ute fed­er­al drug dis­counts.

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis (SIX:NOVN)' blockbuster heart-failure drug Entresto late on Wednesday.

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday. The U.S. Court ...

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...

Basel: Novartis has announced that the Company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the ...

BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure.

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ® (sacubitril/valsartan ...